Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Fiche publication
Date publication
mai 2017
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NOEL Georges
Tous les auteurs :
Lebellec L, Chauffert B, Blay JY, Le Cesne A, Chevreau C, Bompas E, Bertucci F, Cupissol D, Fabbro M, Saada-Bouzid E, Duffaud F, Feuvret L, Bonneville-Levard A, Bay JO, Vauleon E, Vinceneux A, Noel G, Penel N, Mir O
Lien Pubmed
Résumé
To assess the role of first-line Molecular Targeted Therapies (MTTs) in Advanced chordoma (AC) patients.
Mots clés
Anti-EGFR, Antiangiogenics, Chordoma, Imatinib, Molecular targeted therapy, Prognostic factors
Référence
Eur. J. Cancer. 2017 May;79:119-128